Evidence map›Paper›PMID 37790484›Full record

ArticlebioRxiv : the preprint server for biology2023

Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer.

Loretah Chibaya, Christina F Lusi, Kelly D DeMarco, Griffin I Kane, Meghan L Brassil, Chaitanya N Parikh, Katherine C Murphy, Junhui Li, Tiana E Naylor, Julia Cerrutti and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Loretah ChibayaDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Christina F LusiDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA USA.
Kelly D DeMarcoDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Griffin I KaneDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA USA.
Meghan L BrassilDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA USA.
Chaitanya N ParikhDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Katherine C MurphyDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Junhui LiDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Tiana E NaylorDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA USA.
Julia CerruttiDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA USA.
Jessica PeuraDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Jason R PitarresiDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Lihua Julie ZhuDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Katherine A FitzgeraldDivision of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Prabhani U AtukoraleDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA USA.
Marcus RuscettiDepartment of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
University of Massachusetts Chan Medical School · USUniversity of Massachusetts Amherst · US

Funding

Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumorsR00CA241110 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RUSCETTI, MARCUS A. · 2020 to 2022
$747k
Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccinationK22CA262355 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ATUKORALE, PRABHANI · 2021 to 2023
$583k
Dissecting the oncogenic and pro-metastatic roles of PTHLH-mediated calcium signaling in pancreatic cancerK99CA252153 · NCI · UNIVERSITY OF PENNSYLVANIA · PI PITARRESI, JASON R. · 2021 to 2022
$275k
NCI NIH HHS K22 CA262355NCI NIH HHS K99 CA252153NCI NIH HHS R00 CA241110
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma has quickly risen to become the 3

Identifiers

PMID37790484
PMCPMC10542133
OpenAlexW4386852338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.